PMID- 30719802
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20200213
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 49
IP  - 6
DP  - 2019 Jun
TI  - Is there a role for proton pump inhibitor prophylaxis in haematology patients?
PG  - 694-701
LID - 10.1111/imj.14241 [doi]
AB  - While proton pump inhibitors (PPI) are widely prescribed as prophylaxis in 
      selected haematology inpatient and outpatients, an informal survey of haematology 
      units around Australia found wide variations in the specific indications for 
      their use. This is consistent with a literature review which showed a paucity of 
      robust evidence to support their use, specifically in chemotherapy-induced 
      mucositis, thrombocytopenia or administration of high dose glucocorticosteroids 
      in the absence of additional risk factors. Rationalising PPI prescribing is 
      clinically important from both a cost and safety perspective, given the emerging 
      evidence of adverse events associated with prolonged PPI administration. A review 
      of prescribing practices at our institution over a 14-month period found that 
      approximately 60% of myeloma, lymphoma and autograft patients received PPI 
      prophylaxis during and beyond chemotherapy without an accepted indication. We 
      encourage institutions to review their PPI prescribing practices with the intent 
      of rationalising their use, and to conduct studies aiming to fill the substantial 
      gaps in our knowledge.
CI  - (c) 2019 Royal Australasian College of Physicians.
FAU - Leitinger, Emma
AU  - Leitinger E
AUID- ORCID: 0000-0002-4674-3403
AD  - Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, 
      Australia.
FAU - Hui, Lisa
AU  - Hui L
AD  - Department of Clinical Haematology, Austin Hospital, Melbourne, Victoria, 
      Australia.
FAU - Grigg, Andrew
AU  - Grigg A
AD  - Department of Clinical Haematology, Austin Hospital, Melbourne, Victoria, 
      Australia.
AD  - Olivia Newton John Cancer Research Institute and The University of Melbourne, 
      Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
RN  - 0 (Glucocorticoids)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
CIN - Intern Med J. 2019 Oct;49(10):1337. PMID: 31602763
MH  - Australia
MH  - Drug Therapy, Combination
MH  - Gastrointestinal Hemorrhage/chemically induced/*prevention & control
MH  - Glucocorticoids/*adverse effects/therapeutic use
MH  - Hematologic Diseases/drug therapy
MH  - Humans
MH  - Inappropriate Prescribing/*statistics & numerical data
MH  - Inpatients
MH  - Outpatients
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Proton Pump Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
OTO - NOTNLM
OT  - gastrointestinal bleeding
OT  - glucocorticosteroid
OT  - haematology
OT  - proton pump inhibitor
OT  - steroid
EDAT- 2019/02/06 06:00
MHDA- 2020/02/14 06:00
CRDT- 2019/02/06 06:00
PHST- 2018/06/01 00:00 [received]
PHST- 2018/11/27 00:00 [revised]
PHST- 2019/01/27 00:00 [accepted]
PHST- 2019/02/06 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
PHST- 2019/02/06 06:00 [entrez]
AID - 10.1111/imj.14241 [doi]
PST - ppublish
SO  - Intern Med J. 2019 Jun;49(6):694-701. doi: 10.1111/imj.14241.